In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price target of $28.00. The company’s shares closed last Monday at $16.92, close to its 52-week high of $18.25.
According to TipRanks.com, Livshits is a 3-star analyst with an average return of 6.0% and a 45.9% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $24.67.
Based on Replimune Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.51 million. In comparison, last year the company had a GAAP net loss of $6.46 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.